1242269-83-5

Upstream product

• 1242270-11-6 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-(2,2-difluoro-ethoxy)-4-methylamino-5-nitro-benzoic acid amide 
• 1242270-09-2 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-fluoro-4-methylamino-5-nitro-benzoic acid amide 
• 1218943-32-8 trans-4-trifluoromethylcyclohexanamine hydrochloride 
• 933781-52-3 trans-4-(trifluoromethyl)cyclohexanecarboxamide 
• 1242270-10-5 2-fluoro-4-methylamino-5-nitro-benzoic acid 
• 934330-05-9 trans-4-(trifluoromethyl)cyclohexanecarbonyl chloride 
• 153775-33-8 2,4-difluoro-5-nitro-benzoic acid 
• 133261-33-3 trans-4-trifluoro-methyl-cyclohexanecarboxylic acid 

Downstream Products

• 1360622-01-0 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-{2,6-dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoro-ethoxy)-1-methyl-1H-benzimidazole-5-carboxylic acid amide 

Relevant academic research and scientific papers

NEW COMPOUNDS

This invention relates to compounds of formula (I) their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7, R8 have meanings given in the description.

NEW COMPOUNDS

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7, R8 have meanings given in the description.